FILTER
FILTERED INTERVIEW RESULTS
Peter Quarm
DIRECTOR, DUTYLEX
Dutylex explains the challenges of beginning a business distributing industrial lubricants in Ghana and West Arica more generally.
Martin van Gemert
MANAGING DIRECTOR, MINCON WEST AFRICA
Mincon comments on its business with the mining sector in West Africa.
Lorenzo Fiorillo
EVP WEST AFRICA, ENI
ENI updates GBR on the progress of its operations across Sub-Saharan Africa.
Andrew van Zyl
DIRECTOR, SRK CONSULTING (SA)
SRK Consulting is an international consultancy service provider for the natural resource industry, operating in South Africa, DRC and Ghana.
Enoch Kusi-Yeboah
GENERAL MANAGER, METSO MINERALS GHANA
From its offices in Ghana, Metso comments on how its offering is developing alongside the West African mining industry.
Ese Avanoma
GROUP MANAGING DIRECTOR, BRADE GROUP
BRADE was established in 2012 and currently has offices in Nigeria, Ghana and Uganda. The company offers a wide array of services to the African market ranging from energy services solutions, chemical solutions to manufacturing.
Raphael Khalifa
FOUNDER, TEMBO POWER
Tembo Power is developing hydropower projects across Africa with a focus on DRC.
Federico De Simone
CHAIRMAN, DE SIMONE GROUP
De Simone is a Ghanaian indigenous company that started operating in 1964 and has since expanded into various sectors such as power, mining and oil & gas, and currently operates in Ghana, Ivory Coast, Burkina Faso, Nigeria, Liberia, Mali and Guinea.
Guido Brusco
EVP WEST AFRICA, ENI
The Italian E&P company maintains strong levels of activity in Africa.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
